9.4 Chronic Kidney Disease: Staging & Progression Retardation

Chronic kidney disease (CKD) affects over 14% of the United States adult population and is a major multiplier of cardiovascular morbidity and all-cause mortality. The KDIGO 2024 Clinical Practice Guideline established a multi-pillar disease-modifying pharmacotherapy framework designed to arrest progression to end-stage kidney disease (ESKD). In addition to disease retardation, clinicians must expertly manage CKD complications including normocytic anemia, mineral and bone disorder (CKD-MBD), metabolic acidosis, and preemptive planning for renal replacement therapy.

1. KDIGO Staging & Risk Heat Map

CKD is defined as abnormalities of kidney structure or function present for >3 months, with implications for health. Staging requires both a GFR Category (G1–G5) and an Albuminuria Category (A1–A3).

KDIGO Staging Classification Grid

Board Exam Pearl — Cystatin C Confirmatory Testing: Creatinine-based eGFR (CKD-EPI 2021 race-free equation) can be inaccurate in patients with extreme muscle mass (bodybuilders, amputees, severe sarcopenia, paraplegia, cirrhosis) or strict vegetarian/vegan diets. In patients with eGFRcr 45–59 mL/min/1.73m2 without albuminuria, confirm true GFR with Serum Cystatin C (CKD-EPI Creatinine-Cystatin C equation) before diagnosing CKD.

2. The 5 Pillars of CKD Progression Retardation

Modern guideline-directed management of CKD incorporates five disease-modifying pharmacological and lifestyle pillars designed to halt nephron loss and reduce cardiovascular mortality:

Pillar 1: Standardized Blood Pressure Control

• Target: Systolic Blood Pressure (SBP) < 120 mmHg using standardized office blood pressure measurement (KDIGO 2021/2024 guidelines). Supported by the SPRINT trial, which demonstrated reduced all-cause mortality and cardiovascular events without accelerating permanent renal loss.
• If standardized automated office measurement is unavailable, maintain blood pressure <130/80 mmHg.

Pillar 2: Renin-Angiotensin System (RAS) Inhibition

• First-Line Agents: ACE Inhibitors (e.g., Lisinopril, Ramipril) or Angiotensin Receptor Blockers (ARBs) (e.g., Losartan, Valsartan) titrated to the maximally tolerated guideline dose.
• Indications: Strongly recommended for all patients with hypertension, CKD, and moderately increased to severely increased albuminuria (A2: UACR 30–300 mg/g or A3: UACR >300 mg/g), and in all patients with diabetic kidney disease and albuminuria.
• Physiologic Mechanism: Preferentially dilates the efferent arteriole, reducing intraglomerular hydrostatic pressure, decreasing glomerular hyperfiltration injury, and reducing proteinuria.
• The "30% Rule" for Serum Creatinine: An acute rise in serum creatinine of up to 30% (or up to a 30% decline in eGFR) within 2 to 4 weeks of initiating or up-titrating an ACEi/ARB is an expected hemodynamic effect of reduced glomerular pressure. Do NOT discontinue the drug unless the creatinine increase exceeds 30% or refractory hyperkalemia develops.
• Dual RAS Blockade is Strictly Contraindicated: Combining an ACE inhibitor with an ARB (or direct renin inhibitor like Aliskiren) is banned based on the ONTARGET and VA NEPHRON-D trials, which proved that dual blockade increases adverse outcomes (hyperkalemia, acute kidney injury, hypotension) without providing cardiovascular or renal benefit.

Pillar 3: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

• Agents: Empagliflozin 10 mg daily (EMPA-KIDNEY) or Dapagliflozin 10 mg daily (DAPA-CKD) or Canagliflozin 100 mg daily (CREDENCE).
• Indications: Indicated for patients with CKD and eGFR >= 20 mL/min/1.73m2 with UACR >= 200 mg/g (or in diabetic CKD with UACR >= 30 mg/g), regardless of diabetes status.
• Mechanism of Action: Inhibits SGLT2 in the proximal convoluted tubule, increasing distal sodium delivery to the macula densa. This restores tubuloglomerular feedback, inducing afferent arteriolar vasoconstriction, reducing intraglomerular hypertension, and alleviating renal hypoxia.
• Continuation Rule: Causes an expected initial, reversible eGFR "dip" of 3–5 mL/min. Once initiated down to eGFR >=20 mL/min/1.73m2, continue the SGLT2 inhibitor until initiation of maintenance dialysis or transplantation, even if eGFR drops below 20 mL/min/1.73m2.

Pillar 4: Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone)

• Agent: Finerenone (Kerendia) (10 mg daily if eGFR 25–59 mL/min; 20 mg daily if eGFR >=60 mL/min).
• Indications: Indicated in patients with Type 2 Diabetes and CKD who have persistent albuminuria (UACR >=30 mg/g to >5000 mg/g) despite maximum tolerated doses of an ACEi or ARB, provided baseline eGFR is >= 25 mL/min/1.73m2 and serum potassium is <= 4.8–5.0 mEq/L (FIDELIO-DKD and FIGARO-DKD trials).
• Mechanism & Benefits: Selectively blocks the mineralocorticoid receptor with high affinity, preventing aldosterone-driven pro-inflammatory and pro-fibrotic signaling in renal and cardiac tissues. Reduces composite kidney failure outcomes by 18% and major adverse cardiovascular events by 14%.
• Safety Monitoring: Recheck serum potassium and eGFR at 4 weeks following initiation or dose escalation; withhold if K+ >5.5 mEq/L.

Pillar 5: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

• Agent: Semaglutide 1.0 mg weekly SC (Ozempic).
• Evidence (FLOW Trial): In patients with type 2 diabetes and CKD (eGFR 25–75 mL/min/1.73m2 and UACR >300 mg/g on max RAS blockade), Semaglutide demonstrated a 24% relative risk reduction in major kidney disease events, kidney failure, and cardiovascular death.